PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
PFE vs. MRK
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between PFE and MRK is 0.52, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.5

Performance

PFE vs. MRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK). The values are adjusted to include any dividend payments, if applicable.

-25.00%-20.00%-15.00%-10.00%-5.00%0.00%5.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-7.80%
-19.39%
PFE
MRK

Key characteristics

Sharpe Ratio

PFE:

-0.06

MRK:

-0.65

Sortino Ratio

PFE:

0.08

MRK:

-0.77

Omega Ratio

PFE:

1.01

MRK:

0.89

Calmar Ratio

PFE:

-0.02

MRK:

-0.50

Martin Ratio

PFE:

-0.15

MRK:

-1.02

Ulcer Index

PFE:

8.59%

MRK:

13.34%

Daily Std Dev

PFE:

22.99%

MRK:

20.88%

Max Drawdown

PFE:

-54.82%

MRK:

-68.62%

Current Drawdown

PFE:

-50.62%

MRK:

-23.95%

Fundamentals

Market Cap

PFE:

$149.67B

MRK:

$252.08B

EPS

PFE:

$0.75

MRK:

$4.78

PE Ratio

PFE:

35.21

MRK:

20.85

PEG Ratio

PFE:

0.20

MRK:

0.07

Total Revenue (TTM)

PFE:

$45.86B

MRK:

$48.59B

Gross Profit (TTM)

PFE:

$29.87B

MRK:

$36.68B

EBITDA (TTM)

PFE:

$15.61B

MRK:

$19.73B

Returns By Period

In the year-to-date period, PFE achieves a -0.45% return, which is significantly lower than MRK's 0.17% return. Over the past 10 years, PFE has underperformed MRK with an annualized return of 2.35%, while MRK has yielded a comparatively higher 8.46% annualized return.


PFE

YTD

-0.45%

1M

3.24%

6M

-7.80%

1Y

-2.35%

5Y*

-3.20%

10Y*

2.35%

MRK

YTD

0.17%

1M

-1.52%

6M

-19.39%

1Y

-13.71%

5Y*

5.97%

10Y*

8.46%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

PFE vs. MRK — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PFE
The Risk-Adjusted Performance Rank of PFE is 4242
Overall Rank
The Sharpe Ratio Rank of PFE is 4646
Sharpe Ratio Rank
The Sortino Ratio Rank of PFE is 3737
Sortino Ratio Rank
The Omega Ratio Rank of PFE is 3737
Omega Ratio Rank
The Calmar Ratio Rank of PFE is 4747
Calmar Ratio Rank
The Martin Ratio Rank of PFE is 4545
Martin Ratio Rank

MRK
The Risk-Adjusted Performance Rank of MRK is 1818
Overall Rank
The Sharpe Ratio Rank of MRK is 1515
Sharpe Ratio Rank
The Sortino Ratio Rank of MRK is 1616
Sortino Ratio Rank
The Omega Ratio Rank of MRK is 1515
Omega Ratio Rank
The Calmar Ratio Rank of MRK is 1818
Calmar Ratio Rank
The Martin Ratio Rank of MRK is 2525
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

PFE vs. MRK - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for PFE, currently valued at -0.06, compared to the broader market-2.000.002.00-0.06-0.65
The chart of Sortino ratio for PFE, currently valued at 0.08, compared to the broader market-4.00-2.000.002.004.000.08-0.77
The chart of Omega ratio for PFE, currently valued at 1.01, compared to the broader market0.501.001.502.001.010.89
The chart of Calmar ratio for PFE, currently valued at -0.02, compared to the broader market0.002.004.006.00-0.02-0.50
The chart of Martin ratio for PFE, currently valued at -0.15, compared to the broader market0.0010.0020.00-0.15-1.02
PFE
MRK

The current PFE Sharpe Ratio is -0.06, which is higher than the MRK Sharpe Ratio of -0.65. The chart below compares the historical Sharpe Ratios of PFE and MRK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.00AugustSeptemberOctoberNovemberDecember2025
-0.06
-0.65
PFE
MRK

Dividends

PFE vs. MRK - Dividend Comparison

PFE's dividend yield for the trailing twelve months is around 6.36%, more than MRK's 3.13% yield.


TTM20242023202220212020201920182017201620152014
PFE
Pfizer Inc.
6.36%6.33%5.70%3.12%2.64%3.91%3.68%3.12%3.54%3.70%3.48%3.34%
MRK
Merck & Co., Inc.
3.13%3.14%2.72%2.52%3.41%3.03%2.48%2.60%3.36%3.14%3.43%3.12%

Drawdowns

PFE vs. MRK - Drawdown Comparison

The maximum PFE drawdown since its inception was -54.82%, smaller than the maximum MRK drawdown of -68.62%. Use the drawdown chart below to compare losses from any high point for PFE and MRK. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-50.62%
-23.95%
PFE
MRK

Volatility

PFE vs. MRK - Volatility Comparison

Pfizer Inc. (PFE) has a higher volatility of 6.54% compared to Merck & Co., Inc. (MRK) at 5.05%. This indicates that PFE's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%AugustSeptemberOctoberNovemberDecember2025
6.54%
5.05%
PFE
MRK

Financials

PFE vs. MRK - Financials Comparison

This section allows you to compare key financial metrics between Pfizer Inc. and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab